Clinical trial · Interventional
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
A Phase I/II Trial fo Intravenous CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT00017017CI-TRIAL-00010478completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent ovarian epithelial or fallopian tube cancer or primary peritoneal cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Primary Peritoneal Cavity Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paclitaxel poliglumex | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma
* Recurrent disease following prior initial therapy with platinum-based regimen
* No more than 2 prior cytotoxic chemotherapy regimens for recurrent disease
* No more than 1 prior non-platinum, non-taxane regimen
* At least 1 site of radiographically measurable disease AND/OR
* CA-125 levels at least 50% above upper limits of normal for a minimum of 2 samples
PATIENT CHARACTERISTICS:
Age
* Not specified
Performance status
* Karnofsky 70-100%
Life expectancy
* Not specified
Hematopoietic
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic
* Bilirubin less than 1.5 times upper limit of normal (ULN)
* SGOT less than 1.5 times ULN
* Alkaline phosphatase less than 1.5 times ULN
Renal
* Creatinine no greater than 1.5 mg/dL
Other
* No unresolved, pre-existing grade 2 or greater neurotoxicity from prior treatment with neurotoxic drugs
* No active uncontrolled infection
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 4 weeks after study
PRIOR CONCURRENT THERAPY:
Biologic therapy
* At least 4 weeks since prior immunotherapy and recovered
Chemotherapy
* See Disease Characteristics
* At least 4 weeks since prior chemotherapy and recovered
Endocrine therapy
* At least 4 weeks since prior endocrine therapy and recovered
Radiotherapy
* At least 4 weeks since prior radiotherapy (except for palliative reasons) and recovered
Surgery
* Not specified
Other
* At least 4 weeks since other prior investigational drugs and recoveredReferences
Publications (0)
Data not yet available
No reference posted for this study.